Different treatments for Crohn’s disease complicated by severe acute lower gastrointestinal bleeding: infliximab therapy is critical and cannot be ignored
Compared to surgery and traditional therapy (such as somatostatins or octreotide), infliximab therapy could control acute SLGIB in CD as well as achieve similar improvement in hemoglobin level with additional anti-inflammatory effects and lower rebleeding risk. Furthermore, infliximab therapy was found to be more economical than surgery.
Authors
- Mingyan Xie
- Shuoyi Yao
- Fen Wang (ORCID: https://orcid.org/0000-0002-1387-1126)
- Zheng Wang (ORCID: https://orcid.org/0000-0003-4873-505X)
- Shengnan Wu
- Xiaoming Liu
- Yingjuan Feng
Institutions
- Central South University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- The First People's Hospital of Changde (CN)
- Yueyang Hospital (CN)
- Third Xiangya Hospital (CN)
- University of South China (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.3389/fphar.2026.1687439
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Central South University
- Xiangya Hospital, Central South University